A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

• ClinicalTrials.gov Identifier: NCT05090904
• Recruitment Status: Completed
• First Posted: October 25, 2021
• Last Update Posted: March 23, 2023
• Sponsor: Insmed Incorporated
• Information provided by (Responsible Party): Insmed Incorporated

Study Description

Brief Summary:

The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis	Drug: Brensocatib; Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 29 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
• Actual Study Start Date: November 30, 2021
• Actual Primary Completion Date: November 1, 2022
• Actual Study Completion Date: November 1, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Brensocatib 10 mg; Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. The participants will be stratified based on cystic fibrosis transmembrane conductance regulators (CFTRs) modulator treatment.	Drug: Brensocatib; Oral tablet; Other Name: INS1007
Experimental: Brensocatib 25 mg; Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.	Drug: Brensocatib; Oral tablet; Other Name: INS1007
Experimental: Brensocatib 40 mg; Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.	Drug: Brensocatib; Oral tablet; Other Name: INS1007
Experimental: Brensocatib 65 mg; Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.	Drug: Brensocatib; Oral tablet; Other Name: INS1007
Placebo Comparator: Placebo; Participants will be administered a placebo matching brensocatib once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.	Drug: Placebo; Oral tablet

Outcome Measures

Primary Outcome Measures :

1. Maximum Plasma Concentration (Cmax) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose ]
2. Time to Maximum Plasma Concentration (tmax) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose ]
3. Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-dose (AUC0-24) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 hours postdose ]
4. Elimination Half-life (t1/2) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose ]
5. Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) [ Time Frame: Day 1 to Day 56 ]

Secondary Outcome Measures :

1. Dose-normalized Maximum Plasma Concentration (Cmax) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose ]
2. Dose-normalized Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-dose (AUC0-24) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 hours postdose ]
3. Dose-normalized Area Under the Concentration-time Curve from Time 0 to the Time of Last Measurable Concentration (AUClast) of Brensocatib [ Time Frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participants must be ≥18 years of age at the time of signing the informed consent.

• Male or female participants with a confirmed diagnosis of CF related lung disease:

  1. Percent predicted forced expiratory volume in 1 second (ppFEV1) between 40% to 90% (inclusive) at Screening Visit and at Baseline.
  2. Stable CF treatment for at least 30 days before screening and willing to remain on a stable regimen throughout the treatment period.
• Has a body mass index ≥18 kg/m^2.

• Male and female participants must use contraceptives that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  1. Male participants, who are not sterile, with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose.
  2. Women must be postmenopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective contraception methods (i.e., methods that alone or in combination achieve <1% unintended pregnancy rates per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose.
• Female participants of childbearing potential must have a negative serum pregnancy test at Screening.
• Male participants with pregnant or nonpregnant women of childbearing potential partners must use a condom.

Exclusion Criteria:

• Severe or unstable CF, per Investigator's judgement.
• Currently being treated for allergic bronchopulmonary aspergillosis or nontuberculous mycobacteria or tuberculosis.
• Active and current infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
• History of malignancy in the past 5 years, except completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin.
• Established diagnosis of hepatitis B viral infection or positive for hepatitis B surface antigen (HBsAg) at Screening.
• Established diagnosis of hepatitis C virus (HCV) infection at Screening. Participants positive for hepatitis C antibody are eligible only if HCV RNA is negative.
• History of human immunodeficiency virus (HIV) infection.
• Acute upper or lower respiratory tract infection, pulmonary exacerbation, or changes in therapy (including intravenous and oral antibiotics) for pulmonary disease within 4 weeks prior to Day 1 (administration of the first dose of study drug). Participants meeting this criterion could be rescreened 4 weeks after resolution of symptoms.
• History of prolonged QT/QTc interval with QTcF >480 millisecond (msec) at Screening.
• History of solid organ or hematological transplantation.

• Have diagnosed periodontal disease and are either:

  1. Currently treated by a dentist for this condition or
  2. Expected to have periodontal disease-related procedures within the study period.
• Received any live attenuated vaccine within 4 weeks prior Screening.
• Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 90 days prior to Screening.
• Known history of hypersensitivity to brensocatib or any of its excipients.
• Use of any immunomodulatory agents within 4 weeks before the Screening Visit is prohibited during the study through end of study (including, but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, interferon gamma (IFN-γ], and azathioprine).
• Continuous use of high-dose non-steroidal anti-inflammatory drugs (NSAIDs) is prohibited during the study through end of study.
• History of alcohol, medication, or illicit drug abuse.
• Current smoker, as defined by Centers for Disease Control and Prevention: An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.

Contacts and Locations

Locations

United States, Florida

USA001

Gainesville, Florida, United States, 32610-0001

United States, Georgia

USA016

Augusta, Georgia, United States, 30912-0004

United States, Illinois

USA025

Glenview, Illinois, United States, 60025-7645

United States, Massachusetts

USA011

Boston, Massachusetts, United States, 02115-5724

United States, Michigan

USA023

Ann Arbor, Michigan, United States, 48109

United States, Missouri

USA002

Saint Louis, Missouri, United States, 63101

United States, New York

USA022

New York, New York, United States, 10032-3720

United States, Ohio

USA008

Cleveland, Ohio, United States, 44106-1716

USA006

Cleveland, Ohio, United States, 44195-0001

United States, Oregon

USA018

Portland, Oregon, United States, 97239-3011

United States, South Carolina

USA009

Charleston, South Carolina, United States, 29425-8900

United States, Tennessee

USA017

Nashville, Tennessee, United States, 37232-0028

United States, Texas

USA004

Dallas, Texas, United States, 75390-7208

USA003

Tyler, Texas, United States, 75708

Sponsors and Collaborators

Insmed Incorporated

More Information

• Responsible Party: Insmed Incorporated
• ClinicalTrials.gov Identifier: NCT05090904
• Other Study ID Numbers: INS1007-211
• First Posted: October 25, 2021
• Last Update Posted: March 23, 2023
• Last Verified: March 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Insmed Incorporated:

Cystic Fibrosis; Brensocatib

Additional relevant MeSH terms:

Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases